stella
beta
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma — Stella
Recruiting
Back to Neuroblastoma trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(2 sites)
United States
Boston Children's Hospital, Boston, Massachusetts
Dana-Farber Cancer Institute, Boston, Massachusetts
View full record on ClinicalTrials.gov